Table 1. Summary of findings from mouse cancer model studies: function of type 17 lymphocytes.
| Cancer model | Sub-type | Function of type 17 cells (pro- or anti-tumorigenic?) | Ref. |
|---|---|---|---|
| Subcutaneous injection | EL4, CT26 | Pro-tumorigenic | (11) |
| B16 melanoma | Anti-tumorigenic | (12) | |
| MC38 | Anti-tumorigenic | (13) | |
| KPC, Braf-Pten, B16-melanoma | Pro-tumorigenic | (14) | |
| Hepa1-6 HCC | Pro-tumorigenic | (15) | |
| MA782 (orthotopic) | Pro-tumorigenic | (16) | |
| 4T1 (orthotopic) | Pro-tumorigenic | (16,17) | |
| Intraperitoneal injection | ID8 ovarian cancer | Pro-tumorigenic | (18,19) |
| Intravenous injection | B16 melanoma, LLC | Anti-tumorigenic | (20) |
| MC38 | Anti-tumorigenic | (13) | |
| Oncogene-activated | Constitutive MYC expression in early B-cells | Pro-tumorigenic | (21) |
| K14CrexCdh1f/fxTrp53f/f | Pro-tumorigenic | (22) | |
| (KEP) mice spontaneous breast cancer | |||
| KrasG12DxCCSPCre Lung Cancer | Pro-tumorigenic | (23) | |
| KrasLSL-G12Dxp53f/fxSftpcCre Lung Cancer | Pro-tumorigenic | (24) | |
| Ptenf/fxSMAD4f/fxCCSPCre Lung Cancer | Anti-tumorigenic | (25) | |
| Carcinogen-induced | DMBA/TPA-induced skin cancer/squamous cell carcinoma | Pro-tumorigenic | (26,27) |
| AOM DSS APCmin ETBF-induced colon cancer | Pro-tumorigenic | (28,29,30) | |
| Inflammation-accelerated | Helicobacter hepaticus-infected/AOM-treated129SvEvS6.Rag2−/− | Pro-tumorigenic | (31) |
AOM, azoxymethane; DMBA, 7,12-dimethylbenz[a]anthracene; DSS, dextran-sulfate sodium; ETBF, Enterotoxigenic Bacteroides fragilis; HCC, hepatocellular carcinoma; LLC, Lewis lung carcinoma; TPA, 12-O-tetradecanoylphorbol-13-acetate.